Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus, Sirolimus and Methotrexate for GVHD Prophylaxis
NCT00146614Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2002
- Primary completion
- Apr 2003
- Modality
- Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus, tacrolimus and methotrexate in graft-versus-host disease (GVHD), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Incidence and Severity of Graft Versus Host Disease. Started Jul 2002; status: completed.
02
Drugs
sirolimustacrolimusmethotrexate
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00146614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146614.